FLGTFulgent Genetics, Inc.

Billing delays pressured margins, though acquisitions drove anatomic pathology growth.

The latest update on Fulgent Genetics centers on a higher analyst price target, with fair value moving from US$15 to US$19. That shift reflects refreshed views on profitability and valuation, while the Neutral rating signals that analysts see both upside potential and execution risk in balance for now. As you read on, you will see how this new target fits into the broader narrative around Fulgent Genetics and what to watch as the story develops from here. Stay updated as the Fair Value for...

Moby summary of Fulgent Genetics, Inc.'s Q2 2026 earnings call

Despite billing system transition challenges and revised guidance, Fulgent Genetics advances its clinical pipeline and expands its AI-driven diagnostics portfolio.

Fulgent Genetics (NASDAQ:FLGT) reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from Bako Diagnostics and StrataDx. Management also lowered its full-year revenue outlook, citing lower co

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -26.09% and -9.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?